Ovarian cancer has the highest mortality rate among all the gynecological cancers. This is mostly due to the resistance of ovarian cancer to current chemotherapy regimens. Therefore, it is of crucial importance to identify the molecular mechanisms associated with chemoresistance. Methods: NCI/ADR-RES is a multidrug-resistant cell line that is a model for the study of drug resistance in ovarian cancer. We carried out a microarray-derived transcriptional profiling analysis of NCI/ADR-RES to identify differentially expressed genes relative to its parental OVCAR-8. Results: Gene-expression profiling has allowed the identification of genes and pathways that may be important for the development of drug resistance in ovarian cancer. The NCI/ADR-RE...
Background Chemotherapy resistance, especially platinum resistance, is the main cause of poor progno...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...
Anna Vert1,2 Jessica Castro,1,2 Marc Ribó,1,2 Maria Vilanova,1,2 Antoni Benito1,2 1Protein E...
Ovarian cancer, a common malignant tumor, is one of the primary causes of cancer-related deaths in w...
The NIH:OVCAR-3 is a cisplatin refractory cell line established from malignant ascites of a patient ...
Epithelial ovarian cancer is the sixth most common cancer in women worldwide and the most important ...
Copyright © 2014 Radosław Januchowski et al. This is an open access article distributed under the Cr...
Background: Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide....
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by ...
Seventy percent of ovarian cancer patients die due to consecutive episodes of recurrences resulting ...
In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, wit...
Ovarian cancer is a major cause of fatality due to a gynecological malignancy. This lethality is lar...
Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late diagn...
Background Ovarian cancer (OC) is one of the worrisome gynecological cancers worldwide. Given its c...
Background Chemotherapy resistance, especially platinum resistance, is the main cause of poor progno...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...
Anna Vert1,2 Jessica Castro,1,2 Marc Ribó,1,2 Maria Vilanova,1,2 Antoni Benito1,2 1Protein E...
Ovarian cancer, a common malignant tumor, is one of the primary causes of cancer-related deaths in w...
The NIH:OVCAR-3 is a cisplatin refractory cell line established from malignant ascites of a patient ...
Epithelial ovarian cancer is the sixth most common cancer in women worldwide and the most important ...
Copyright © 2014 Radosław Januchowski et al. This is an open access article distributed under the Cr...
Background: Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide....
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by ...
Seventy percent of ovarian cancer patients die due to consecutive episodes of recurrences resulting ...
In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, wit...
Ovarian cancer is a major cause of fatality due to a gynecological malignancy. This lethality is lar...
Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late diagn...
Background Ovarian cancer (OC) is one of the worrisome gynecological cancers worldwide. Given its c...
Background Chemotherapy resistance, especially platinum resistance, is the main cause of poor progno...
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sensitive ...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...